Centene To Invest $100 Million In Alzheimer’s, Diabetes Research At Washington University

Multi-national health care organization Centene Corporation (Centene) recently announced it will be funding up to $100 million in Alzheimer’s research at Washington University School of Medicine. In addition to Alzheimer’s, some of the funding will also help pay for research into breast cancer, diabetes, and obesity, as well.

As part of the agreement, Centene’s funds will be distributed over a 10 year period to the university’s Personalized Medicine Initiative. Any innovation emerging from the initiative will be jointly commercialized through both the Washington University School of Medicine and Centene.

Centene Corporation, a Fortune 100 company . . .